Intrathecal drug delivery (IDD) is an innovative approach ... and advancements in IDD systems, highlighting their potential benefits for patients who do not respond well to conventional pain ...

The blood–brain barrier is the biggest challenge to the development of drugs that target the CNS. Most capillary beds leak plasma contents between and across endothelial cells by way of window-like ...

Following FDA clearance of its investigational new drug (IND) application in ... directly targeting the central nervous system. This targeted delivery approach is designed to address the safety ...

intrathecal delivery of therapeutics into the spinal canal or subarachnoid space of the brain, and the use of nanoparticles to improve drug delivery. Lilly's involvement will add a new dimension ...

Zolgensma is the world’s most expensive drug, with a price tag of more ... reported additional safety and efficacy data with intrathecal delivery of the gene therapy – i.e. delivery into ...

Whole-body positron emission tomography at the time of diagnosis showed no evidence of central nervous system (CNS) involvement ... He was ultimately enrolled in a clinical trial of intrathecal ...

directly targeting the central nervous system. This targeted delivery approach is designed to address the safety and efficacy challenges associated with systemic gene therapies. By focusing the ...

Rheumatoid arthritis (RA) is an autoimmune disorder affecting millions worldwide, causing chronic inflammation, debilitating ...

A DGIST research team, led by Professor Kyung-In Jang, has developed a smart patch capable of real-time biometric signal ...

The new treatment targets inflammation directly within the joints so that therapeutic agents are released only when needed.

Panelists discuss how careful patient selection and management of potential complications - including surgical risks, ...